Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Bayer Pharma Aktiengesellschaft

Monica Schenone

Matthew Meyerson

Heidi Greulich

Ulrike Sack

Xiaoyun Wu

Alex Burgin

Luc De Waal

Philip Lienau

Knut Eis

Antje Margret Wengner

Timothy A Lewis

Martin Lange

Ulricke Sack

The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Compounds, compositions and methods for cancer patient stratification and cancer treatment

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Compositions and methods for cancer expressing PDE3A or SLFN12

The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein). 

Growing community of inventors

Boston, MA, United States of America

Monica Schenone